^
Association details:
| Biomarker: | FGFR2 C382R |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Pemazyre (pemigatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
36P - A point mutation replacing Cysteine with Arginine at position 382 (C382R) in the transmembrane domain of FGFR2 leads to response to FGF2-inhibitor Pemigatinib in chemo-refractory intrahepatic cholangiocarcinoma
Published date:
03/03/2022
Excerpt:
A 74-year-old male was diagnosed with iCCA in liver segments seven and eight with infiltration of the hepatic veins and inferior vena cava revealed a C382R mutation of the intramembrane domain of FGRR2 receptor....In our case report, we were able to show that the patient in whom an C382R mutation was detected responded to the therapy with pemigatinib.
Source:
Title:
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Published date:
11/20/2020
Excerpt:
FIGHT-202 (NCT02924376), a phase II, open-label, multicenter, global study of pemigatinib in patients with previously treated advanced or metastatic cholangiocarcinoma...3 of the 4 patients treated with pemigatinib who had FGFR2 p.C382R mutations achieved a best overall response of stable disease, with a PFS of 6.9, 4.0, and 9.0 months.
DOI:
10.1158/2159-8290.CD-20-0766
Trial ID:
Test:
